Chris@NNW, Author at NetworkNewsWire

TuesdayMar 19, 2019 1:30 pm

Cytori Therapeutics Inc. (NASDAQ: CYTX) Attends 31st Annual ROTH Conference

Cytori Therapeutics (NASDAQ: CYTX) is developing, manufacturing and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine and Cell Therapy franchises, respectively. Cytori Nanomedicine is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. Cytori Cell Therapy, prepared within several hours with the proprietary Celution System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. For more…

TuesdayMar 19, 2019 1:30 pm

Cypress Semiconductor Corp. (NASDAQ: CY) Attends 31st Annual ROTH Conference

Cypress Semiconductor (NASDAQ: CY) provides advanced embedded solutions for the world’s most innovative automotive, industrial, smart home appliances, consumer electronics and medical products. Cypress’ microcontrollers, wireless and USB-based connectivity solutions, analog ICs, and reliable, high-performance memories help engineers design differentiated products and get them to market first. Cypress is committed to providing customers with the best support and development resources on the planet enabling them to disrupt markets by creating new product categories in record time. For more information, visit the company's website at www.cypress.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1)…

TuesdayMar 19, 2019 1:30 pm

Remark Holdings Inc. (NASDAQ: MARK) Attends 31st Annual ROTH Conference

Remark Holdings (NASDAQ: MARK) delivers an integrated suite of AI solutions that enable businesses and organizations to solve problems, reduce risk and deliver positive outcomes. The company's easy-to-install AI products are being rolled out in a wide range of applications within the retail, financial, public safety and workplace arenas. The company also owns and operates digital media properties that deliver relevant, dynamic content and ecommerce solutions. The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Chengdu and Hangzhou, China. For more information, visit the company's website at www.remarkholdings.com. About NetworkNewsWire…

TuesdayMar 19, 2019 1:30 pm

Reed’s Inc. (NYSE American: REED) Attends 31st Annual ROTH Conference

Reed's (NYSE American: REED) has sold over 500 million bottles of its category leading natural, handcrafted beverages. Reed’s is America’s No. 1 selling Ginger Beer brand. Virgil’s is America’s No. 1 selling independent, full line of natural craft sodas. The Reed’s Inc. portfolio is sold in over 30,000 retail locations across the natural, specialty, grocery, drug, club and mass channels nationwide. Reed’s Ginger Beers are unique to the category because of the proprietary process of hand brewing its award-winning products. The company uses the same handcrafted approach and dedication to the highest quality ingredients in its award-winning Virgil’s line of…

TuesdayMar 19, 2019 1:30 pm

RedHill Biopharma Ltd. (NASDAQ: RDHL) Attends 31st Annual ROTH Conference

RedHill Biopharma (NASDAQ: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases and cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. For more information, visit the company's website at www.redhillbio.com.…

TuesdayMar 19, 2019 1:30 pm

Recro Pharma Inc. (NASDAQ: REPH) Attends 31st Annual ROTH Conference

Recro Pharma (NASDAQ: REPH) is a specialty pharmaceutical company focused on products for hospitals and ambulatory care settings currently developing non-opioid products for the treatment of acute pain. The company’s lead product candidate is a proprietary injectable form of meloxicam. Intravenous (IV), meloxicam has successfully completed multiple phase 2 clinical trials for the treatment of moderate to severe pain. Recro believes injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. For more information, visit the company's website at www.recropharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and…

TuesdayMar 19, 2019 1:30 pm

RealNetworks Inc. (NASDAQ: RNWK) Attends 31st Annual ROTH Conference

RealNetworks (NASDAQ: RNWK) invented the streaming media category and changed the way audio and video content was consumed across devices and around the world. Building on a legacy of digital media expertise and innovation, RealNetworks has created a new generation of products that employ best-in-class artificial intelligence and machine learning to enhance and secure our daily lives. For more information, visit the company's website at www.realnetworks.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most…

TuesdayMar 19, 2019 1:00 pm

Q BioMed Inc. (QBIO) Attends 31st Annual ROTH Conference

Q BioMed (OTCQB: QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label…

TuesdayMar 19, 2019 1:00 pm

Purple Innovation Inc. (NASDAQ: PRPL) Attends 31st Annual ROTH Conference

Purple Innovation (NASDAQ: PRPL) is an innovative comfort product company that designs and manufactures products to improve people's lives. It designs and manufactures a range of comfort products, including mattresses, pillows, and cushions, using its patented Hyper-Elastic Polymer material designed to improve comfort. The company markets and sells its products through its direct-to-consumer online channel, traditional retail partners, and third-party online retailers. For more information, visit the company's website at www.purple.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries…

TuesdayMar 19, 2019 1:00 pm

Pulmatrix Inc. (NASDAQ: PULM) Attends 31st Annual ROTH Conference

Pulmatrix (NASDAQ: PULM) is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, inhaled anti-fungal itraconazole for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). In addition, Pulmatrix has partnered with Vectura Group plc to develop Pulmatrix's long-acting muscarinic antagonist drug candidate, PUR0200, for COPD for the U.S. market. For more information, visit the company's website at www.pulmatrix.com. About…